Penwest Pharmaceuticals Co. reported a first quarter net loss of $6.3 million or $0.28 per share, compared with a net loss of $8.9
million or $0.41 per share in the same quarter last year. Total revenues for the first quarter were $965,000, compared with $982,000 in the year-ago quarter.
Trading Markets
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Clears Viseon’s Voyant System
The device allows the surgeon to change the depth of focus and view the surgical site on HD flat-panel display monitors.
FDA Advisory Committee Nixes Trevena’s Opioid in Tight Vote
The FDA concluded there was insufficient evidence for a safety advantage compared to morphine.
FDAnews Drug Daily Bulletin
PENWEST PHARMA POSTS Q1 LOSS/SHARE NARROWER THAN ESTIMATES
April 28, 2006